CoreTissue BioEngineering pushes ACL device strategy beyond early safety testing

ACL surgery needs better graft choices. CoreTissue BioEngineering’s CT-ACL001 now faces the harder randomized test.

ACL surgery needs better graft choices. CoreTissue BioEngineering’s CT-ACL001 now faces the harder randomized test.

SurGenTec won FDA 510(k) clearance for TiLink navigation instruments. Read what this means for SI joint fusion adoption, workflow, and competition.